BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mavrostobart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Mavrostobart\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05431270-2614@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Mavrostobart: Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Mavrostobart\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-CD73 mAb
 \, Administered Alone and in Combination With a PD-1 Inhibitor or Chemothe
 rapy (the MORNINGSTAR Study)\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/mavrostobart#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05431270
URL:https://assetmemo.bio/drug/mavrostobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
